

Special Issue

Targeting Hallmarks of Cancer

Message from the Guest Editor

Cancer remains one of the most significant challenges in modern medicine, characterized by its complexity, heterogeneity, and ability to evolve rapidly. The pursuit of new, efficient drugs to combat cancer is a top priority in biomedical research. However, the development of such therapies is not a straightforward process. It requires a deep understanding of the fundamental mechanisms driving cancer progression, including the hallmark traits of cancer cells and the intricate signaling pathways involved in maintaining the tumor phenotype. In this context, the creation and utilization of biological models, such as organotypic cell cultures, and the study of epigenetic regulators, like long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), are crucial for advancing our ability to develop effective anti-cancer drugs. You may choose our [Joint Special Issue](#) in *Cancers*.

Guest Editor

Prof. Dr. Carlos Pérez Plasencia

1. Laboratorio de Genómica, Instituto Nacional de Cancerología, Tlalpan 14080, México
2. Unidad de Biomedicina, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México (UNAM), Tlalnepantla 54090, Mexico

Deadline for manuscript submissions

25 January 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/218184

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)